The O
mechanism O
may O
be O
related O
to O
the O
improvement O
of O
Ca B
( O
2 O
+ O
) O
handling O
. O

Nonketotic O
hyperglycinemia O
is O
a O
disorder O
of O
amino O
acid O
metabolism O
in O
which O
a O
defect O
in O
the O
glycine B
cleavage O
system O
leads O
to O
an O
accumulation O
of O
glycine B
in O
the O
brain O
and O
other O
body O
compartments O
. O

Over O
the O
following O
9 O
days O
, O
the O
symptoms O
improved O
and O
plasma O
bilirubin B
levels O
were O
normal O
after O
12 O
weeks O
without O
methimazole B
. O

Enhanced O
stimulus O
- O
induced O
neurotransmitter O
overflow O
in O
epinephrine B
- O
induced O
hypertensive O
rats O
is O
not O
mediated O
by O
prejunctional O
beta O
- O
adrenoceptor O
activation O
. O

Compared O
with O
the O
young O
group O
, O
the O
elderly O
group O
had O
greater O
scopolamine B
- O
induced O
impairment O
in O
word O
recall O
60 O
, O
90 O
and O
120 O
minutes O
after O
administration O
( O
p O
< O
0 O
. O
05 O
) O
. O

NIK B
- I
247 I
, O
tacrine B
and O
E B
- I
2020 I
all O
strongly O
inhibited O
acetylcholinesterase O
( O
AChE O
) O
in O
human O
red O
blood O
cells O
( O
IC50s O
= O
1 O
. O
0 O
x O
10 O
( O
- O
6 O
) O
, O
2 O
. O
9 O
x O
10 O
( O
- O
7 O
) O
and O
3 O
. O
7 O
x O
10 O
( O
- O
8 O
) O
M O
, O
respectively O
) O
. O

RESULTS O
: O
No O
lymphocyte O
proliferation O
was O
observed O
either O
in O
the O
patient O
or O
in O
the O
healthy O
volunteer O
in O
the O
presence O
of O
dilevalol B
solutions O
. O

Passage O
of O
mannitol B
into O
the O
brain O
around O
gliomas O
: O
a O
potential O
cause O
of O
rebound O
phenomenon O
. O

Haloperidol B
- O
induced O
catalepsy O
was O
challenged O
with O
prior O
intracollicular O
microinjections O
of O
glutamate B
NMDA B
receptor O
antagonists O
, O
MK B
- I
801 I
( O
15 O
or O
30 O
mmol O
/ O
0 O
. O
5 O
microl O
) O
and O
AP7 B
( O
10 O
or O
20 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
, O
or O
of O
the O
NMDA B
receptor O
agonist O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
, O
20 O
or O
30 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
. O

During O
a O
ten O
- O
year O
period O
, O
348 O
women O
were O
studied O
for O
a O
total O
of O
5 O
, O
877 O
patient O
months O
in O
four O
separate O
studies O
relating O
oral B
contraceptives I
to O
changes O
in O
hematologic O
parameters O
. O

The O
dose O
of O
UFH B
was O
changed O
according O
to O
the O
activated O
clotting O
time O
level O
. O

AZT B
has O
induced O
a O
macrocytic O
anemia O
in O
AIDS O
patients O
on O
long O
term O
AZT B
therapy O
. O

The O
disease O
occurred O
subsequent O
to O
the O
initiation O
of O
heparin B
therapy O
for O
suspected O
pelvic O
thrombophlebitis O
and O
cleared O
rapidly O
subsequent O
to O
its O
discontinuation O
. O

Behavioral O
and O
cardiorespiratory O
responses O
to O
a O
lethal O
dose O
of O
morphine B
were O
evaluated O
in O
rats O
pretreated O
with O
saline O
or O
naloxazone B
, O
an O
antagonist O
of O
high O
- O
affinity O
mu O
1 O
opioid O
receptors O
. O

In O
the O
present O
study O
we O
aimed O
to O
investigate O
plasma O
levels O
of O
CGRP O
during O
headache O
induced O
by O
the O
NO B
donor O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
16 O
patients O
with O
chronic O
tension O
- O
type O
headache O
and O
16 O
healthy O
controls O
. O

In O
addition O
, O
crocin B
in O
the O
mentioned O
dose O
could O
significantly O
attenuated O
learning O
and O
memory O
impairment O
in O
treated O
STZ B
- O
injected O
group O
in O
passive O
avoidance O
test O
. O

We O
investigated O
in O
this O
study O
the O
possible O
engagement O
of O
locus O
coeruleus O
of O
the O
pons O
in O
this O
phenomenon O
, O
using O
male O
Sprague O
- O
Dawley O
rats O
anesthetized O
with O
ketamine B
. O

Liver O
and O
plasma O
TBARs B
were O
not O
increased O
until O
14 O
days O
( O
2 O
- O
fold O
vs O
. O
control O
, O
p O
< O
0 O
. O
05 O
) O
. O

Our O
hypothesis O
is O
that O
a O
vagal O
mechanism O
mediated O
by O
azithromycin B
could O
be O
the O
pathogenesis O
of O
hiccups O
in O
our O
patient O
. O

The O
high O
ratio O
is O
believed O
to O
impart O
the O
low O
frequency O
of O
extrapyramidal O
symptoms O
with O
risperidone B
at O
low O
dosages O
. O

It O
is O
widely O
believed O
that O
dopamine B
( O
DA B
) O
mediates O
methamphetamine B
( O
METH B
) O
- O
induced O
toxicity O
to O
brain O
dopaminergic O
neurons O
, O
because O
drugs O
that O
interfere O
with O
DA B
neurotransmission O
decrease O
toxicity O
, O
whereas O
drugs O
that O
increase O
DA B
neurotransmission O
enhance O
toxicity O
. O

The O
toxic O
effects O
of O
tacrine B
- O
loaded O
poly B
- I
L I
- I
lactid I
acid I
nanoparticles O
( O
5mg O
/ O
kg O
) O
, O
a O
saline O
solution O
of O
tacrine B
( O
5mg O
/ O
kg O
) O
and O
an O
empty O
colloidal O
nanoparticle O
suspension O
were O
compared O
following O
i O
. O
p O
. O
administration O
in O
LiCl B
- O
pre O
- O
treated O
Wistar O
rats O
. O

The O
weakness O
in O
these O
patients O
is O
due O
to O
pathology O
at O
both O
the O
neuromuscular O
junction O
( O
most O
likely O
due O
to O
ND B
- I
NMBA I
) O
and O
muscle O
( O
most O
likely O
due O
to O
corticosteroids B
) O
. O

METHODS O
: O
This O
was O
a O
prospective O
, O
single O
- O
intervention O
study O
of O
consenting O
adult O
patients O
undergoing O
procedural O
sedation O
with O
propofol B
between O
December O
28 O
, O
2002 O
, O
and O
October O
31 O
, O
2003 O
. O

Two O
phase O
II O
trials O
of O
24 O
- O
hour O
paclitaxel B
infusions O
in O
chemotherapy O
- O
naive O
patients O
with O
stage O
IIIB O
or O
IV O
non O
- O
small O
cell O
lung O
cancer O
( O
NSCLC O
) O
reported O
response O
rates O
of O
21 O
% O
and O
24 O
% O
. O

